natgillin/translations-raw huggingface dataset:
Infections and infestations: Not known: 
Infekcije i infestacije: Nepoznato:
Severe hepatic impairment (Child-Pugh classification C). 
Teško oštećenje funkcije jetre (Child-Pugh stadij C).
Conventional long-term studies to evaluate the carcinogenic potential of hydroxycarbamide have not been performed. 
Klasične dugoročne studije u cilju procjenjivanja kancerogenog potencijala hidroksikaramida nisu se provodile.
Toxic ranges of myelosuppression as described in section 4.2. 
Toksična mijelosupresija sukladno vrijednostima navedenim u dijelu 4.2.
An updated RMP shall be submitted on a yearly basis. 
Dopunjeni RMP podnosi svake godine.
In an open single-dose study in adult patients with Sickle Cell Syndrome (Yan JH et al, 2005) the influence of renal function on pharmacokinetics of hydroxycarbamide was assessed. 
U otvorenoj studiji jednokratnog doziranja kod odraslih bolesnika sa sindromom srpastih stanica (Yan JH et al, 2005) ocijenjivao se utjecaj renalne funkcije na farmakokinetiku hidroksikarbamida.
The MAH must implement this educational plan nationally, prior to marketing, and as agreed with the competent authorities in the Member States 
Nositelj odobrenja obvezan je ovaj plan edukacije provesti na nacionalnoj razini prije stavljanja lijeka na tržište i u skladu s dogovorom postignutim s nadležnim tijelima u zemljama članicama.
For the storage of unused broken tablets, see section 5 “How to store Siklos”. 
Upute o čuvanju neiskorištenih tableta pročitajte u dijelu 5 „Kako čuvati Siklos“.
België/Belgique/Belgien 
België/Belgique/Belgien Addmedica
Hence, no interaction is to be expected in case of concomitant administration with substances being substrates of cytochromes P450 or P-glycoprotein. 
Stoga se ne očekuje interakcija u slučaju istodobne primjene tvari koje su supstrati citokroma P450 ili P-glikoproteina.
Systemic and cutaneous lupus erythematous 
sistemski i kožni eritemski lupus
Continuous follow-up of the growth of treated children and adolescents is recommended. 
Preporučuje se kontinuirano praćenje rasta djece i adolescenti koja primaju terapiju.
30 tablets 
90 tableta
Under exceptional circumstances a maximum dose of 35 mg/kg b.w./day might be justified under close haematological monitoring (see section 4.4). 
U iznimnim slučajevima maksimalna doza od 35 mg/kg tjelesne težine/dnevno može biti opravdana uz strogo praćenje hematoloških parametara (vidjeti dio 4.4).
If blood counts are within the toxic range Siklos should be temporarily discontinued until blood counts recover. 
Ako broj krvnih stanica padne unutar toksičnih vrijednosti, terapiju Siklosom treba privremeno prekinuti, dok se ne oporavi normalan broj krvnih stanica.
Anyone handling Siklos should wash their hands before and after contact with the tablets. 
Svatko tko rukuje Siklosom treba prije i nakon doticaja s tabletom oprati ruke.
Because of the rarity of long term data on treatment with hydroxycarbamide in children less than 2 years of age, dose regimens have not been established and thus, in this population, the treatment with hydroxycarbamide is not recommended. 
Zbog malobrojnih dugoročnih podataka o terapiji hidroksikarbamidom u djece mlađe od 2 godine, nisu ustanovljeni režimi doziranja te se stoga za ovu populaciju liječenje hidroksikarbamidom ne preporučuje.
It is unknown whether this leukemogenic effect is secondary to hydroxycarbamide or is associated with the patient's underlying disease. 
Nije poznato je li taj leukemogeni učinak sekundarni učinak hidroksikarbamida ili je povezan s osnovnom bolešću bolesnika.
1 Haematological recovery usually occurs within two weeks of withdrawal of hydroxycarbamide. 
1 Krvna se slika obično oporavlja unutar dva tjedna nakon prekida uzimanja hidroksikarbamida.
Haemodialysis reduced the exposure to hydroxycarbamide by 33% (see sections 4.2 and 4.4). 
Hemodijalizom je izloženost hidroksikarbamidu smanjena za 33% (vidjeti dio 4.2 i 4.4).
Generally, the patient's antibody response to vaccines may be decreased. 
Općenito, bolesnikova reakcija antitijela na cjepivo može biti umanjena.
Detailed information on this medicine is available on the European Medicines Agency website http://www.ema.europa.eu/. 
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove http://www.ema.europa.eu.
Based on the limited amount of available information, in case of an exposure to hydroxycarbamide of pregnant female patients or pregnant partners of male patients, treated by hydroxycarbamide, a careful follow-up with adequate clinical, biological and ultrasonographic examinations should be considered. 
Na temelju ograničene količine dostupnih informacija, u slučaju izloženosti trudnih bolesnica ili trudnih partnerica muških bolesnika liječenih hidroksikarbamidom treba razmotriti pažljivo praćenje putem odgovarajućih kliničkih, bioloških i ultrazvučnih pretraga.
The biotransformation pathways as well as the metabolites are not fully characterised. 
Nisu u potpunosti utvrđeni putevi biotransformacije ni metaboliti.
• As soon as the tablet is disintegrated, swallow the content of the teaspoon. 
• Čim se tableta rastopi, progutajte sadržaj čajne žličice.
5 How to store Siklos Contents of the pack and other information 
Kako čuvati Siklos Sadržaj pakiranja i druge informacije
The time to reach maximum plasma concentration and the percentage of the dose excreted in urine were increased in children compared to adults. 
Vrijeme potrebno za dostizanje maksimalne koncentracije u plazmi i postotak doze koji se izlučio u urin bili su povećani kod djece, u usporedbi s vrijednostima kod odraslih bolesnika.
In case of non-response (re-occurrence of crises or no decrease in crisis rate) the daily dose may be increased by steps of 2.5 to 5 mg/kg b.w./day using the most appropriate strength. 
Ako nema odgovora kod bolesnika (recidiv krize ili izostanak smanjenja stope javljanja krize) dnevna se doza može povećati u koracima od 2,5 do 5 mg/kg tjelesne težine/dnevno do postizanja najprikladnije jačine doze.
For patients who are not able to swallow the tablets, these can be disintegrated immediately before use in a small quantity of water in a teaspoon. 
Bolesnici koji ne mogu progutati tabletu mogu je neposredno prije uzimanja otopiti u maloj količini vode u čajnoj žličici.
Each half of tablet is embossed “H” on one side. 
Svaka polovica tablete ima otisnuto slovo „H“ na jednoj strani.
Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu. 
Detaljnijee informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu.
When the maximum tolerated dose is not reached transient myelotoxicity usually occurs in less than 10% of patients, while under the maximum tolerated dose more than 50% can experience reversible bone marrow suppression. 
Kada nije postignuta maksimalna podnošljiva doza, prolazna mijelotoksičnost obično se javlja u manje od 10% bolesnika, dok je kod maksimalno podnošljive doze kod više od 50% bolesnika zabilježena reverzibilna supresija koštane srži.
The maximum plasma levels and the apparent volume of distribution related to body weight were well comparable between age groups. 
Maksimalne plazmatske koncentracije i prividni volumen distribucije prema težini tijela bili su usporedivi između dobnih skupina.
• Treatment guide for physicians 
• Vodič za terapiju namijenjen liječnicima
Siklos has minor influence on the ability to drive and use machines. 
Siklos malo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Luxembourg/Luxemburg 
Luxembourg/Luxemburg Addmedica
Very rare side effects (may affect up to 1 in 10,000 people) or unknown frequency (frequency cannot be estimated from the available data): 
Vrlo rijetke nuspojave (mogu se javiti kod do 1 na 10 000 osoba) ili nuspojave nepoznate učestalosti (učestalost nije moguće procijeniti na temelju dostupnih podataka):
In patients with a creatinine clearance ≤ 60 ml/min the initial Siklos dose should be decreased by 50%. 
Kod bolesnika s klirensom kreatinina ≤ 60 ml/min početnu dozu Siklosa treba smanjiti za 50%.
Also, in rats testicular atrophy with decreased spermatogenesis occurred, while in dogs reversible spermatogenic arrest was noted. 
Kod štakora se osim toga pojavila atrofija testisa sa smanjenjem spermatogeneze, dok je kod pasa zabilježen reverzibilan zastoj spermatogeneze.
Siklos must not be administered to patients with severe renal impairment (creatinine clearance < 30 ml/min) (see sections 4.3, 4.4 and 5.2). 
Siklos se ne smije primjenjivati bolesnicima s teškim oštećenjem bubrega (klirens kreatinina < 30 ml/min) (vidjeti dijelove 4.3, 4.4 i 5.2).
The estimated volume of distribution of hydroxycarbamide approximates total body water. 
Procijenjeni volumen distribucije hidroksikarbamida približan je ukupnom volumenu vode u tijelu.
Beside the inconstant correlation between reduction of crisis rate and the increase in HbF, the cytoreductive effect of hydroxycarbamide, particularly the drop of neutrophils, was the factor with the strongest correlation to a reduced crisis rate. 
Osim nepostojane korelacije između smanjenja učestalosti kriza i povećanja HbF, citoredukcijski učinak hidroksikarbamida, a naročito pad neutrofila, predstavlja faktor koji je u najjačoj korelaciji sa smanjenjem učestalosti kriza.
3 Mainly due to an infection with Parvovirus or a splenic sequestration. 
3 Većinom radi infekcije parvovirusom ili sekvestracije u slezeni.
People who are not taking Siklos and in particular pregnant women should avoid being in contact with hydroxycarbamide. 
Ljudi koji ne uzimaju Siklos, a naročito trudnice, moraju izbjegavati doticaj s hidroksikarbamidom.
You can add a drop of syrup or mix the content with food to mask a possible bitter taste. 
Možete dodati kapljicu sirupa ili lijek pomiješati s hranom kako biste prikrili mogući gorak okus.
In case the prescribed dose requires breaking the tablet in halves or quarters, this should be done out of the reach of food. 
Ako zbog propisane doze tabletu treba prelomiti na dva ili četiri dijela, to je potrebno učiniti podalje od hrane.
Treatment with Siklos requires close clinical monitoring. 
Terapija Siklosom zahtijeva strogo kliničko praćenje.
Patients treated with hydroxycarbamide in combination with didanosine, stavudine, and indinavir showed a median decline in CD4 cells of approximately 100/mm3. 
Kod bolesnika liječenih hidroksikarbamidom u kombinaciji s didanozinom, stavudinom i indinavirom primijećen je medijan smanjenja CD4 stanica od oko 100/mm3.
Inflammation of the skin causing red scaly patches and possibly occurring together with pain in the joints. 
Upala kože koja uzrokuje crvene ljuskave mrlj e i može se pojaviti zajedno s boli u zglobovima.
There are no data that support specific dose adjustments in patients with hepatic impairment. 
Ne postoje podaci koji podupiru specifično prilagođavanje doze kod bolesnika sa oštećenjem jetre.
Specifically, the safety of hydroxycarbamide had been examined retroactively from cohorts of 123 adults over 13 years and 352 children older than 2 years and adolescents up to 12 years. 
Sama sigurnost primjene hidroksikarbamida ispitivala se retroaktivno u kohorti od 123 odrasla bolesnika tijekom 13 godina i u 352 djece starije od 2 godine i adolescenta tijekom do 12 godina.
In paediatric patients, the half-life was slightly longer and the total clearance related to body weight slightly higher than in adult patients (see section 4.2). 
Kod pedijatrijskih bolesnika poluvijek je bio nešto duži, a ukupni klirens u odnosu na težinu tijela blago povišen u usporedbi s odraslim bolesnicima vidjeti dio 4.2).
Siklos therapy can then be re-initiated at a lower dose (see section 4.2). 
Terapiju Siklosom moguće je nakon toga ponovno uvesti u smanjenoj dozi (vidjeti dio 4.2).
The oral bioavailability of hydroxycarbamide is almost complete as assessed in indications other than Sickle Cell Syndrome. 
Oralna bioraspoloživost hidroksikarbamida je gotovo potpuna kako je procijenjeno u drugim indikacijama osim sindroma srpastih stanica.
In the human, according to a retrospective analysis of a cohort of 123 adult patients treated with hydroxycarbamide, twenty-three pregnancies have been reported from 15 women treated with hydroxycarbamide and partners of 3 men treated with hydroxycarbamide. 
Kod ljudi su, na temelju retrospektivne analize kohorte od 123 odrasla bolesnika koji su liječeni hidroksikarbamidom, zabilježene 23 trudnoće kod 15 žena liječenih hidroksikarbamidom i kod partnerica trojice muškaraca koji su primali hidroksikarbamid.
Some cells become abnormal, rigid and take a crescent or sickle shape which leads to anemia. 
Neke stanice postaju abnormalne, krute i poprimaju oblik mjeseca odnosno postaju srpaste što dovodi do anemije.
During treatment with Siklos, blood counts must be monitored every two weeks at treatment initiation (i.e. for the first two months) and if the daily dose of hydroxycarbamide is up to 35 mg/kg b.w. 
Tijekom terapije Siklosom broj krvnih stanica mora se redovito kontrolirati svaka dva tjedna na početku terapije (tj. tijekom prva dva mjeseca) i ako dnevna doza hidroksikarbamida iznosi do 35 mg/kg tjelesne težine/dnevno.
In nearly all clinical studies conducted in Sickle Cell Syndrome, hydroxycarbamide reduced the frequency of vaso-occlusive episodes by 66% to 80%, in children and in adults. 
U gotovo svim kliničkim studijama provedenima kod sindroma srpastih stanica, hidroksikarbamid je smanjio učestalost vazookluzivnih epizoda za 66% do 80% kod djece i odraslih.
Long-term data on the continued use of hydroxycarbamide in patients with Sickle Cell Syndrome are available in children and adolescents, with a follow-up of 12 years in children and adolescents and over 13 years in adults. 
Dugoročni podaci o kontinuiranoj primjeni hidroksikarbamida u bolesnika sa sindromom anemije srpastih stanica dostupni su za djecu i adolescente, uz razdoblje praćenja do 12 godina za djecu i adolescente i više od 13 godina za odrasle.
HbF interferes with the polymerisation of HbS and thus impedes the sickling of red blood cell. 
HbF interferira s polimerizacijom HbS i na taj način sprječava deformacije eritrocita.
In patients with Sickle Cell Syndrome, neutropenia was reported in isolated cases of hydroxycarbamide overdose (1.43 times and 8.57 times of the maximum recommended dose of 35 mg/kg b.w./day). 
U bolesnika sa sindromom srpastih stanica neutropenija je zabilježena u izoliranim slučajevima predoziranja hidroksikarbamidom (1,43 puta i 8,57 puta više od maksimalne preporučene doze od 35 mg/kg tjelesne težine/dnevno).
Urea is one metabolite of hydroxycarbamide. 
Urea je jedan od metabolita hidroksikarbamida.
Each quarter of tablet is embossed “T” on one side. 
Svaka četvrtina tablete ima otisnuto slovo „T“ na jednoj strani.
Treatment of overdose consists of gastric lavage, followed by symptomatic treatment and control of bone marrow function. 
Liječenje predoziranja sastoji se od ispiranja želuca nakon čega slijedi simptomatsko liječenje i kontrola funkcije koštane srži.
• Need for periodic blood counts 
• Potrebu za periodičnim krvnim pretragama
Hydroxycarbamide may decrease sperm production in male patients while they are being treated. 
Hidroksikarbamid može smanjiti proizvodnju spermija kod muških bolesnika, za vrijeme liječenja.
If you forget to take Siklos 
Ako ste zaboravili uzeti Siklos
In addition hydroxycarbamide causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or protein. 
Osim toga, hidroksikarbamid izaziva trenutačnu inhibiciju sinteze DNK jer djeluje kao inhibitor ribonukleotidne reduktaze, bez utjecaja na sintezu ribonukleinske kiseline ili proteina.
Thrombocytopenia (< 80 x 109/L), anaemia (haemoglobin < 4.5 g/dl)3 
trombocitopenija (< 80 x 109/L), anemija (hemoglobin < 4,5 g/dl)3
Treatment with Siklos should be discontinued if bone marrow function is markedly depressed. 
Liječenje Siklosom treba prekinuti ako se funkcija koštane srži znatno smanji.
Male and female patients on hydroxycarbamide wishing to conceive should stop treatment 3 to 6 months before pregnancy if possible. 
Bolesnici i bolesnice koji uzimaju hidroksikarbamid, a žele začeti dijete, terapiju moraju prekinuti 3 do 6 mjeseci prije moguće trudnoće.
Rarely, ulcers are caused by leukocytoclastic vasculitis. 
U rijetkim slučajevima ulkuse su uzrokovani leukocitoklastičnim vaskulitisom.
The most frequently reported adverse reaction is myelosuppression with neutropenia as the most common manifestation. 
Najčešće zabilježena nuspojava je mijelosupresija najčešće manifestirana kao neutropenija.
Patients and/or parents or the legal responsible person must be able to follow directions regarding the administration of this medicine, their monitoring and care. 
Bolesnici i/ili roditelji ili zakonski skrbnici bolesnika moraju biti u stanju slijediti upute o primjeni ovog lijeka, redovitim kontrolama i njezi.
Parvovirus B19 infection Neoplasms, benign, malignant and unspecified Not known: 
infekcija parvovirusom B19 Dobroćudne, zloćudne i nespecificirane novotvorine Nepoznato:
Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic Sickle Cell Syndrome (see section 5.1). 
Siklos je indiciran u prevenciji rekurentnih bolnih vazookluzivnih kriza koje uključuju akutni prsni sindrom kod odraslih, adolescenata i djece starije od 2 godine koji boluju od simptomatskog sindroma srpastih stanica (vidjeti dio 5.1).
Cardiovascular effects and haematological changes were observed in some species. 
Kod nekih vrsta primijećeni su kardiovaskularni učinci i hematološke promjene.
Phone: +33 1 72 69 01 86 Fax: +33 1 73 72 94 13 
Telefon: +33 1 72 69 01 86 Faks: +33 1 73 72 94 13
Haemoglobin < 4.5 g/dl 
Hemoglobin < 4,5 g/dl Retikulociti
Due to potentially severe clinical outcomes for the cutaneous vasculitic ulcers reported in patients with myeloproliferative disease, hydroxycarbamide should be discontinued and/or its dose reduced if cutaneous vasculitic ulcerations develop. 
Zbog potencijalno teških kliničkih ishoda kožnih vaskulitičnih ulkusa prijavljenih u bolesnika s mijeloproliferativnim bolestima, hidroksikarbamid treba prekinuti i/ili smanjiti dozu, ako se razviju kožne vaskulitične ulceracije.
Low blood cell counts (myelosuppression), enlargement of red blood cells, decreased resistance to infections. 
Smanjeni broj krvnih stanica (mijelosupresija), povećanje veličine crvenih krvnih stanica, smanjena otpornost na infekcije.
Potentially fatal pancreatitis and hepatotoxicity, and severe peripheral neuropathy have been reported in HIV-infected patients who received hydroxycarbamide in combination with antiretroviral medicinal products, particularly didanosine plus stavudine. 
Potencijalno fatalni pankreatitis i hepatotoksičnost te teška periferna neuropatija zabilježeni su u bolesnika zaraženih virusom HIV koji su primali hidroksikarbamid u kombinaciji s antiretrovirusnim lijekovima i to naročito didanozinom i stavudinom.
In the event a patient does still not respond when treated with the maximum dose of hydroxycarbamide (35 mg/kg b.w./day) over three to six months, permanent discontinuation of Siklos should be considered. 
Ako bolesnik i dalje ne odgovara na liječenje s maksimalnom dozom hidroksikarbamida (35 mg/kg tjelesne težine/dnevno) u trajanju od tri do šest mjeseci, potrebno je razmisliti o trajnom prekidu terapije Siklosom.
Because of the potential for serious adverse reactions in infants, breast-feeding must be discontinued while taking Siklos. 
Zbog potencijalnih ozbiljnih nuspojava u dojenčadi, dojenje se tijekom uzimanja Siklosa mora prekinuti.
Wash your hands before and after contact with the tablets. 
Prije i nakon doticaja s tabletama operite ruke.
Sickle Cell disease is an inherited blood disorder that affects the disc shaped red cells of the blood. 
Bolest srpastih stanica je nasljedni poremećaj krvi koji pogađa crvene krvne stanice u obliku diska.
As long as the patient responds to therapy either clinically or haematologically (e.g. increase of haemoglobin F (HbF), Mean Corpuscular Volume (MCV), neutrophil count) the dose of Siklos should be maintained. 
Sve dok bolesnik reagira na terapiju klinički ili hematološki (npr. povećanjem vrijednosti hemoglobina F (HbF), prosječnog volumena crvenih krvnih stanica (MCV), broja neutrofila) dozu Siklosa treba održavati.
Any person, in particular pregnant women, who are not taking Siklos should avoid direct contact with the parts when breaking a tablet. 
Sve osobe koje ne uzimaju Siklos, a naročito trudnice, moraju izbjegavati neposredan doticaj s dijelovima lijeka kod lomljenja tablete.
In patients with leg ulcers, Siklos should be used with caution. 
Kod bolesnika s ulkusima nogu Siklos treba primjenjivati s oprezom.
If you become pregnant or plan to become pregnant while taking Siklos, your doctor will discuss with you the potential benefits and risks of continuing using Siklos. 
Ako tijekom uzimanja Siklosa ostanete trudni ili planirate zatrudnjeti, liječnik će s Vama raspraviti potencijalne koristi i rizike nastavka terapije Siklosom.
Women of childbearing potential/Contraception in males and females Women of childbearing age receiving hydroxycarbamide should be advised to avoid becoming pregnant, and to inform the treating physician immediately should this occur. 
Žene reproduktivne dobi/Kontracepcija kod muškaraca i žena Žene reproduktivne dobi koje primaju hidroksikarbamid treba savjetovati da moraju izbjegavati trudnoću, a ako do začeća ipak dođe o tome moraju odmah obavijestiti liječnika.
At concentrations ranging from 10 to 300 µM, hydroxycarbamide does not stimulate the in vitro ATPase activity of recombinant human P glycoprotein (PGP), indicating that hydroxycarbamide is not a PGP substrate. 
In vitro u koncentracijama u rasponu od 10 do 300 µM, hidroksikarbamid ne stimulira aktivnost ATPaze rekombinantnog humanog P glikoproteina (PGP), što ukazuje da hidroksikarbamid nije supstrat PGP-a.
Siklos is used to prevent painful crises, including sudden chest pain, caused by Sickle Cell disease, in adults, adolescents and children older than 2 years. 
Siklos se uzima za prevenciju bolnih kriza, uključujući i iznenadnu bol u prsnom košu izazvanu bolešću srpastih stanica kod odraslih, adolescenata i djece starije od 2 godine.
Hydroxycarbamide administered to male rats at 60 mg/kg b.w./day (about double the recommended usual maximum dose in humans) produced testicular atrophy, decreased spermatogenesis and significantly reduced their ability to impregnate females. 
Hidroksikarbamid koji se davao mužjacima štakora u dozi od 60 mg/kg tjelesne težine/dnevno (oko dvostruko više od preporučene maksimalne doze za ljude) izazvao je atrofiju testisa, smanjenje spermatogeneze i značajno smanjenje njihove sposobnosti da oplode ženke.
Depending on these results your doctor will adjust your dose of Siklos. 
Ovisno o nalazima pretraga liječnik će prilagoditi dozu Siklosa.
The haematological status of the patient, as well as renal and hepatic functions should be determined prior to, and repeatedly during treatment. 
Krvnu sliku bolesnika kao i funkciju bubrega i jetre potrebno je utvrditi prije početka terapije i tijekom terapije redovito kontrolirati.
UNIQUE IDENTIFIER- HUMAN READABLE DATA 
JEDINSTVENI IDENTIFIKATOR - PODACI ČITLJIVI LJUDSKIM OKOM PC:
Acute mucocutaneous toxicity has been reported in patients receiving hydroxycarbamide at doses several times above the therapeutic dose. 
Akutna mukokutana toksičnost zabilježena je u bolesnika koji primaju hidroksikarbamid u dozama nekoliko puta većim od terapijske doze.
Very common reversible oligo- and azoo-spermia have been observed in man, although these disorders are also associated with the underlying disease. 
Vrlo često su kod muškaraca primijećene reverzibilna oligospermija i azoospermija iako se ti poremećaji mogu povezati i s već postojećom bolešću.